These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 7689787)

  • 1. Big cost savings from small filgrastim unit doses.
    Sinsabaugh DK; Freyer DR
    Am J Hosp Pharm; 1993 Jul; 50(7):1363-4. PubMed ID: 7689787
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost considerations in therapy with myeloid growth factors.
    Glaspy JA; Jakway J
    Am J Hosp Pharm; 1993 Jul; 50(7 Suppl 3):S19-26. PubMed ID: 7689789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost benefit and clinical efficacy of low-dose granulocyte colony-stimulating factor after standard chemotherapy in patients with non-Hodgkin's lymphoma.
    Hashino S; Morioka M; Irie T; Shiroshita N; Kawamura T; Suzuki S; Iwasaki H; Umehara S; Kakinoki Y; Kurosawa M; Kahata K; Izumiyama K; Kobayashi H; Onozawa M; Takahata M; Fujisawa F; Kondo T; Asaka M
    Int J Lab Hematol; 2008 Aug; 30(4):292-9. PubMed ID: 18665826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sterility of unit dose syringes of filgrastim and sargramostim.
    Singh RF; Corelli RL; Guglielmo BJ
    Am J Hosp Pharm; 1994 Nov; 51(22):2811-2. PubMed ID: 7531941
    [No Abstract]   [Full Text] [Related]  

  • 5. High cost medicines.
    Atkinson H
    N Z Med J; 1994 Mar; 107(973):88. PubMed ID: 7515484
    [No Abstract]   [Full Text] [Related]  

  • 6. [Filgrastim in the treatment of severe neutropenia in a patient with bilobar pneumonia].
    Marcos Sánchez F; Juárez Ucelay F; Plaza Díaz R; Durán Pérez-Navarro A
    An Med Interna; 1995 Feb; 12(2):100-1. PubMed ID: 7538330
    [No Abstract]   [Full Text] [Related]  

  • 7. Low-dose filgrastim therapy for chronic neutropenia.
    Kaczmarski RS; Mufti GJ
    N Engl J Med; 1993 Oct; 329(17):1280-1. PubMed ID: 7692296
    [No Abstract]   [Full Text] [Related]  

  • 8. [Colony stimulating factors in blood formation].
    Goebel M
    Infusionsther Transfusionsmed; 1994 Nov; 21 Suppl 3():51-6. PubMed ID: 7531048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Filgrastim: new indication. AIDS-associated neutropenia: another soft indication.
    Prescrire Int; 2001 Aug; 10(54):106-7. PubMed ID: 11718177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using filgrastim efficiently.
    Dranitsaris G
    Pharmacoeconomics; 1996 May; 9(5):466-8. PubMed ID: 10161379
    [No Abstract]   [Full Text] [Related]  

  • 11. The costs of treating febrile neutropenia in six U.K. Hospitals.
    Leese B
    Eur J Cancer; 1993; 29A Suppl 7():S15-8. PubMed ID: 7508725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of granulocyte colony-stimulating factor in the treatment of fever and neutropenia in a heart transplant patient.
    Gordon MS; O'Donnell JA; Mohler ER; Cooper MA
    J Heart Lung Transplant; 1993; 12(4):706-7. PubMed ID: 7690254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Myeloid growth factors. New indications with many questions].
    Palmblad J; Samuelsson J; Glimelius B; Ljungman P; Nilsson PG
    Lakartidningen; 1994 Jul; 91(28-29):2675-8. PubMed ID: 7519704
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and safety of two different rG-CSF preparations in the treatment of patients with severe congenital neutropenia.
    Carlsson G; Ahlin A; Dahllöf G; Elinder G; Henter JI; Palmblad J
    Br J Haematol; 2004 Jul; 126(1):127-32. PubMed ID: 15198743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic analysis of filgrastim use for patients with acute myeloid leukaemia in the UK: a comparison of collection methods of resource use data.
    Standaert B; Goldstone J; Lu ZJ; Erder MH; Yin JL
    Pharmacoeconomics; 2002; 20(10):665-74. PubMed ID: 12162755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sterility of repackaged filgrastim and sargramostim.
    Kleinberg ML
    Am J Health Syst Pharm; 1995 May; 52(10):1101. PubMed ID: 7544685
    [No Abstract]   [Full Text] [Related]  

  • 17. Use of decision analysis to evaluate the costs and benefits of filgrastim (G-CSF) therapy.
    Peroutka JA; Mutnick AH
    Formulary; 1995 Jul; 30(7):394-5, 400-4. PubMed ID: 10151731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating resource use and cost of prophylactic management of neutropenia with filgrastim.
    Annemans L; Van Overbeke N; Standaert B; Van Belle S
    J Nurs Manag; 2005 May; 13(3):265-74. PubMed ID: 15819840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based review.
    Bhana N
    Curr Opin Oncol; 2007 Jul; 19(4):328-35. PubMed ID: 17545795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of granulocyte colony stimulating factor (G-CSF) in reversing neutropenia in renal allograft recipients.
    Peddi VR; Hariharan S; Schroeder TJ; First MR
    Clin Transplant; 1996 Feb; 10(1 Pt 1):20-3. PubMed ID: 8652892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.